Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: Psoriasis is a chronic immune-medicated inflammatory condition that affects 2-3% of the population , which is characterized by rash, silver scaling of the skin and can lead to psoriatic arthritis. There are multiple regimens for the treatment of psoriasis including biologic agent, phototherapy and apremilast. Apremilast is an oral phosphodiesterase inhibitor that has been approved as a mono therapy by the FDA in March 2014 for the treatment of psoriatic arthritis and September 2014 for the treatment of moderate to severe plaque psoriasis. While monotherapy with biologic agents is effective for many patients with psoriasis some patients are not satisfied by the outcome and require combination therapy.
Methods: This was retrospective study, open label study carried out at a single center. Twenty-two patients diagnosed with plaque psoriasis and psoriatic arthritis according to American college of Rheumatology criteria-participated. Apremilast was added to their current biologic agent. Patients were permitted to continue their current biologic treatment.
Conclusion: Apremilast can be safely and effectively combined with biologic agents in patients with plaque psoriasis or psoriatic arthritis not responding adequately to these agents alone. No major side effects of cancer or sever infection were reported other than nausea and/or vomiting that were manageable in some patients
To cite this abstract in AMA style:Metyas S, Messiah R, Gettas T, Asfahani L, Quismorio A. Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). http://acrabstracts.org/abstract/combination-therapy-of-apremilast-and-biologic-agent-as-a-safe-option-of-psoriatic-arthritis-and-psoriasis/. Accessed June 24, 2017.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - http://acrabstracts.org/abstract/combination-therapy-of-apremilast-and-biologic-agent-as-a-safe-option-of-psoriatic-arthritis-and-psoriasis/